Comparative Pharmacology
Head-to-head clinical analysis: WEZLANA versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WEZLANA versus WILPO.
WEZLANA vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
IV: 500 mg every 12 hours over 60 minutes.
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown